Test alpelisib plus trametinib for hard-to-treat meningiomas
Treatments studied
Part of Brain & nervous system, Cancer clinical trials.
This Phase 1 trial studies whether combining two targeted medicines—alpelisib and trametinib—can shrink or slow progressive meningiomas that have already been treated with standard surgery and radiation. If you qualify, you may help test a new treatment approach for tumors that keep growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a meningioma confirmed by pathology (biopsy/surgery), grade I, II, or III
- Your meningioma has grown on MRI within the last 3 to 6 months, with two different MRI scans showing growth
- Surgery won’t be able to fully cure it anymore, and you have already tried radiation and/or focused radiation
- You can safely take both drugs (no reason you can’t take alpelisib or trametinib)
- Your body’s key functions are strong enough (bone marrow, liver, and kidneys) for treatment
- You are not pregnant or breastfeeding, and if you could get pregnant you use effective birth control
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial studies cabozantinib, a targeted pill medicine, for meningioma that has come back or is getting worse after standard treatment like surgery or radiation. It aims to shrink tumors and slow progression when other options may have limited benefit.
This trial tests a type of radiation (protons) for brain tumors called atypical or anaplastic meningiomas that need radiotherapy. It may help by aiming radiation more precisely while also learning the safest and most effective dose.
This trial tests a combination of two oral drugs, IN10018 and dalpiciclib, for people with progressive meningioma (a type of brain tumor) that has not responded to standard treatments. The goal is to see if this combination can help shrink or slow the tumor.
This trial tests a combination of two drugs (everolimus and 177Lu-DOTATATE) for people with grade 2 or 3 meningioma that has grown despite prior treatments. It aims to see if this combination can slow or stop tumor growth.
This trial tests a drug called Zanzalintinib for people with meningioma that has come back or grown despite past treatments. It aims to see if the drug can stop or slow tumor growth.
This trial tests a combination of two drugs, alpelisib and pembrolizumab, for people with advanced triple-negative breast cancer or melanoma that has spread. The goal is to see if the combination can help shrink tumors, including those that have spread to the brain.
Hear when a new Meningioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.